Beyond the Basics: A Deep Dive into Blood and Marrow Transplant (BMT) and Cell Therapy (CT)

Calling all experienced inpatient and outpatient BMT/CT nurses! This course comprehensively examines the latest blood and marrow transplants (BMT) and cell therapy (CT) advancements. During this class, you will hear from world-class providers who will help equip you with the knowledge to provide exceptional patient care. Why is this relevant? BMT and CT have revolutionized patient care for various conditions, from hematologic malignancies to solid tumor cancers. Nurses play a pivotal role in this rapidly growing field. By attending this course, you'll be able to describe how immunotherapy cells fight cancer and gain a deeper understanding into how new BMT and CT therapies work and their outcomes. Additionally, you will be able to discuss the role of genetics in BMT CT care and how implicit bias can affect this.

Are you ready to elevate your expertise and provide exceptional care for BMT and CT patients? Join us for this engaging and informative course! Recordings are from our live course offered on 10/30/2025.

You are required to complete all the modules, pass the post-test, and complete the evaluation to attain a CE Certificate.  The passing score is 70%. There are 3 attempts for the post-test.

1. Understand how new BMT and CT treatments work and their outcomes
2. Recall different approaches to discussing genetic considerations with patients and providers and how implicit bias can affect these discussions.
3. Describe the rationale for different types of cell therapies used to treat solid tumors.

SHC Employee: $70.00

Regular Fee: $105.00

Please be sure to pay with a credit card, if payment is not received, your registration will be incomplete and you will not be registered for the course.

Cancellation & Refund Policy:

NO REFUNDS ALLOWED

1. Stanford Health Care is provider approved by the California Board of Registered Nursing (BRN).  Provider Number CEP12165.
2. Stanford Health Care Center for Education, Research, and Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. *Neither SHC nor ANCC endorse any commercial products

©2025 by Stanford Health Care, Division of Patient Care Services.
All rights reserved. No audio or video taping allowed. We reserve the right to make program changes. All students must be registered, attend the entire course, and submit an evaluation after course completion to earn credit hours.

Mitigation of Relevant Financial Relationships

Stanford Health Care (SHC) adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Karen Kalaw, MSN
Stanford Health Care

Content Expert

Nothing to disclose

Theresa Latchford, MS
Stanford Health Care

Content Expert

Speakers Bureau-Bristol-Myers Squibb (Relationship has ended)|Speakers Bureau-Gilead|Speakers Bureau-Autolus

Diana Mazur, MSN
Stanford Health Care

Content Expert

Nothing to disclose

Sally Arai, MD
Stanford Health Care

Faculty

Nothing to disclose

Allison Betof, MD
Stanford University

Faculty

Consulting Fee-Adaptimmune (Relationship has ended)|Grant or research support-Replimune|Grant or research support-Immunocore (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-cTRL Therapeutics (Relationship has ended)|Consulting Fee-Bristol-Myers Squibb (Relationship has ended)|Consulting Fee-Genmab (Relationship has ended)|Consulting Fee-Immatics (Relationship has ended)|Consulting Fee-IO Biotech (Relationship has ended)|Consulting Fee-Iovance Biotherapeutics|Consulting Fee-Novartis AG (Relationship has ended)|Consulting Fee-Merck and Company, Inc.|Consulting Fee-Pfizer, Inc. (Relationship has ended)|Consulting Fee-Replimune|Grant or research support-Bristol-Myers Squibb|Grant or research support-Iovance Biotherapeutics (Relationship has ended)|Grant or research support-Obsidian Therapeutics|Consulting Fee-Delcath|Consulting Fee-GE Healthcare Bio-Sciences (Relationship has ended)|Consulting Fee-Immatics|Grant or research support-Immatics|Advisor-Resolute Bio|Grant or research support-Obsidian Therapeutics

Daniel Fishman, MD
Stanford University School of Medicine

Faculty

Nothing to disclose

Matthew Frank, MD
Stanford

Faculty

Grant or research support-Allogene Therapeutics|Honoraria-Gilead|Grant or research support-Gilead|Grant or research support-Adaptive Biotechnologies|Honoraria-Adaptive Biotechnology |Honoraria-ADC Therapeutics (Relationship has ended)|Grant or research support-Pepromene Bio|Grant or research support-Cargo Therapeutics (Relationship has ended)|Consulting Fee-Bristol-Myers Squibb|Consulting Fee-Johnson & Johnson

Robert Negrin, MD
Stanford University

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Orca Bio|Consulting Fee-Re-Stem|Consulting Fee-Amgen|Consulting Fee-Biorasi

Misha Rashkin, MS, MS, CGC
Stanford Health Care

Faculty

Ownership-Helix LLC

Brian J Scott, MD
Stanford University

Faculty

Honoraria-Gilead (Relationship has ended)|Consulting Fee-Legend Biotherapeutics (Relationship has ended)

Kun-Wei Song, MD
Stanford Health Care

Faculty

Nothing to disclose

Heidi Warpack, MSN
Stanford Health Care

Nurse Planner (CEPD Staff Only)

Nothing to disclose